彭珧,张怡轩,郑更新
PENG Yao1,ZHANG Yi-xuan1,ZHENG Geng-xin2(1.School of Pharmaceutical Engineering

• 1:沈阳药科大学制药工程学院
• 2:沈阳药科大学制药工程学院
• 3:东北制药总厂 辽宁沈阳110016
• 4:辽宁沈阳110016

摘要(Abstract)：

目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。方法综述了最新发现的小分子酪氨酸激酶抑制剂的化学结构、抗肿瘤作用及其作用机制及其发展方向等内容。结果结论蛋白酪氨酸激酶与细胞的增殖、分化、迁移和凋亡有着密切的关系,在细胞生命活动的信号转导途径中扮演着十分关键的角色,筛选酪氨酸激酶抑制剂已经成为开发抗肿瘤药物的新途径。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase(PTK).Methods This article reviewed some new tyrosine kinase inhibitors(TKI) about their chemical structures,anticancer-effect;mechanism of action and development.Results and Conclusions Protein tyrosine kinase(PTK) plays very important role in cellular multiplication,differentiation,immigration and apoptosis closely,which acts as an important role in the cellular significance signal transduction pathway.So screening of tyrosine kinase inhibitor(TKI) has become a new channel to exploit new anti-cancer drugs.

关键词(KeyWords)： 蛋白酪氨酸激酶;酪氨酸激酶抑制剂;信号转导;抗肿瘤药物
protein tyrosine kinase;tyrosine kinase inhibitor(TKI);signal transduction;anticancer drug

Abstract:

Keywords:

基金项目(Foundation): 沈阳市科学技术计划项目(1053125-1-42)

作者(Author): 彭珧,张怡轩,郑更新
PENG Yao1,ZHANG Yi-xuan1,ZHENG Geng-xin2(1.School of Pharmaceutical Engineering

参考文献(References)：

• [1]LI S,GERALD M.Inhibition of tumor angiogenesis bysynthetic receptor tyrosine kinase inhibitors[J].DrugsDiscovery Today,2000,5(8):344-353.
• [2]DORIANO F,DAVID P,ALEX M.Protein tyrosinekinase inhibitors:new treatment modalities[J].CurrentOpinion in Pharmacology,2002,2(4):374-381.
• [3]SATYAJIT KM,DAVID DS.Integrin-regulatedFAK-Src signaling in normal and cancer cells[J].Current Opinion in Cell Biology,2006,18(5):516-523.
• [4]NICOLA N,ANTONELLA DL,CATERINA B,et al.Epidermal growth factor receptor(EGFR)signaling incancer[J].Gene,2006,366(1):2-16.
• [5]李萍,孙正.小分子酪氨酸激酶抑制剂在全身及口腔癌治疗中的研究进展[J].北京口腔医学,2005,13(4):260-264.
• [6]PAWSON T.Regulation and targets of receptor tyro-sine kinases[J].European Journal of Cancer,2002,38(5):S3-S10.
• [7]SALOMON DS,BRANDT R,CIARDIELLO F,et al.Epidermal growth factor-related peptides and theirreceptors in human malignancies[J].Critical Reviewsin Oncology/Hematology,1995,19(1):183-232.
• [8]任晓岚,汪鑫,李志裕,等.表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的研究进展[J].中国新药杂志,2005,14(7):821-826.
• [9]张小彤,李龙芸.表皮生长因子受体酪氨酸激酶抑制剂抗肿瘤治疗的临床进展[J].中国肺癌杂志,2002,5:310-312.
• [10]张敏,张新,白春.表皮生长因子受体与酪氨酸激酶抑制剂在肿瘤防治中的应用进展[J].中国癌症杂志,2003,13:275-278.
• [11]孙忠实,朱珠,韩风英.酪氨酸激酶抑制剂-伊马替尼[J].中国药学杂志,2003,38(1):69-71.
• [12]庄东平.抗肿瘤新药酪氨酸激酶抑制剂STI571研究进展[J].药学实践杂志,2005,23(6):353-356.
• [13]谵台林芳,冯茹.ST1571对急性非淋巴细胞白血病分化及CD117分化抗原影响[J].中国医师杂志,2005,7(5):615-616.
• [14]TOUFENG J,HAJIME N,TAKAHIRO T.ST1571(Glivec)suppresses the expression of vascular endothe-lial growth factor in the gastrointestinal stromal tumorcell line,GIST-T1[J].World Journal of Gastroen-terology,2006,4(5):703-708.
• [15]余和平,徐晶.抗肿瘤药物—格列卫[J].世界临床药物,2003,24(8):503-506.
• [16]任欢,李殿俊,RAINOV NG.ST1571对恶性多发性神经胶质母细胞瘤(GBM)的体外抑瘤作用[J].中国肿瘤临床,2004,31(15):856-859.
• [17]DONATO NJ,WU J,LING Y,et al.The Src/Abl in-hibitor BMS-354825 overcomes resistance to imatinibmesylate in chronic myelogenous leukemia cellsthrough multiple mechanisms[J].Blood,2004,104(11):549-556.
• [18]LI SG,HU YG,SWERDLOW SJ,et a1.Simultaneoustargeting of Scr and Bcr-Abl kinase by BMS-354825 cures Ph+acute lymphoblastic 1eukemia inmice[J].Blood,2004,104(11):545-546.
• [19]CHRISTOPH W,MARTIN S.Novel targeted thera-pies to overcome imatinib mesylate resistance in chron-ic myeloid leukemia(CML)[J].Critical Reviews inOncology/Hematology,2006,57(2):145-164.
• [20]傅明伟,王建祥.BMS-354825:一种新的酪氨酸激酶抑制剂[J].国外医学输血及血液学分册,2005,28(6):532-535.
• [21]DOUILLARD JY,NATALE R,GIACCONE G.ZD1839(“Iressa”)provides clinically significant anti-tumor activity and improves disease-related symptomsin pretreated patients with advanced non-small-celllung cancer(NSCLC):results of two Phase II trials(IDEAL 1 and IDEAL 2)[J].European Journal ofCancer,2002,38(7):56-57.
• [22]MIKA F,KATSUYA M,SACHIKO N,et al.En-hancement of radiosensitivity by dual inhibition of theHER family with ZD1839(“Iressa”)and trastuzumab(”Herceptin”)[J].International Journal of RadiationOncology Biology Physics,2006,61(2):528-536.
• [23]ILARIA B,SERGIO B,CLAUDIA C,et al.Targetingof EGFR tyrosine kinase by ZD1839(“Iressa”)in an-drogen-responsive prostate cancer in vitro[J].Molec-ular Genetics and Metabolism,2006,88(2):114-122.
• [24]YARDEN Y.The EDFR family and its ligands in hu-man cancer;signaling mechanisms and therapeutic op-portunities[J].European Journal of Cancer,2001,37(4):S3-S8.
• [25]WAKELING AE.Epidermal growth factor receptortyrosine kinase inhibitors[J].Current Opinion in Phar-macotherapy,2002,2(4):382-387.
• [26]张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950.
• [27]陈拮,戴媛媛,汤致强.小分子EGFR酪氨酸激酶抑制剂盐酸埃罗替尼[J].中国新药杂志,2005,l4(l0):1227-1229.
• [28]PEREZ SR,CHACHOUA A,HAMMOND LA,et al.Determinants of tumor response and survival with er-lotinib in patients with non-small-cell lung cancer[J].Clinical Oncology,2004,22(16):3238-3247.
• [29]MASATERN M,TAMITO S,SOUICHIROU Y,etal.Induction of apoptosis by ionizing radiation andCI-1033 in HuCCT-1 cells[J].Biochemical andBiophysical Research Communications,2004,19(1):114-119.
• [30]GIACCONE G,HERBST RS,MANEGOLD C,et a1.Gefitinib in combination with gemcitabine and cisplatinin advanced non-small-cell lungcancer:phaseⅢtrim2 intact[J].Clinical Oncology,2004,22(9):777-784.
• [31]ZHOU H,KIM YS,PELETIER A,et al.Effects ofthe EGFR/HER2 kinase inhibitor GW572016 onEGFR and HER2-overexpressing breast cancer cellline proliteration radiosensitization,and resistance[J].International journal of Radiation Oncology BiologyPhysics,2004,58(2):344-352.
• [32]MYERS JN,HOLSINGER FC,BEKELE BN,et al.Targeted molecular therapy for oral cancer with epi-dermal growth factor blockade:a preliminary report[J].Otolaryngology-Head and Neck Surgery,2002,128(8):875-879.
• [33]DAVID WF.Inhibitor of the epidermal growth factorreceptor family of tyrosine kinases as an approach tocancer chemotherapy:progression from reversible to ir-reversible inhibitors[J].Clinical Pharmacology Thera-peutics,1999,82(2-3):207-318.
• [34]NARUO Y,SHINZOH K,TATSUO K,et al.EKB-569,a new irreversible epidermal growth factor recep-tor tyrosine kinase inhibitor,with clinical activity inpatients with non-small cell lung cancer with acquiredresistance to gefitinib[J].Lung Cancer,2006,51(3):363-368.
• [35]丘学德,刘乔保,王田,等.酪氨酸激酶抑制剂PD168393对HER2不同表达水平膀胱癌细胞株的作用研究[J].中国肿瘤防治杂志,2006,13(8):604-607.
• [36]GRIDELLI C,ROSSI A,MAIONE P.New antiangio-genetic agents and non-small cell lung cancer[J].Critical Reviews in Oncology/Hematology,2006,60(1)76-86.